secondary progressive multiple sclerosis
Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis
... with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312” (protocol number CBAF312A2304 sponsored by Novartis Phar- maceuticals; ...Excellence ...
15
Extensive White Matter Dysfunction in Cognitively Impaired Patients with Secondary Progressive Multiple Sclerosis
... with secondary-progressive multiple sclerosis (median age: 55 years, female/male: 27/18, median Expanded Disability Status Scale Score: ...
6
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis
... Relapsing-remitting multiple sclerosis (RRMS) (orange triangles) vs control (green circles), (B) secondary progressive multiple sclerosis (SPMS) (blue squares) vs control (green ...
9
Benign versus secondary progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability
... The differences observed in chronic plaques in the two groups of patients were independent of the size of the lesions measured. The frequency of lesions that filled less than 25% of the VOI was similar in both ...
7
Demyelinating Plaques in Relapsing remitting and Secondary progressive Multiple Sclerosis: Assessment with Diffusion MR Imaging
... Our results indicate that the orientationally av- eraged coefficient , D . is able to show the dis- tinction between relapsing-remitting and second- ary-progressive MS plaques. In addition, this parameter ...
7
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
... UK Multiple Sclerosis Society and National Multiple Sclerosis ...in multiple sclerosis funded by: Receptos, Novartis, Roche and Biogen-Idec, and has received an investigator ...
16
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
... SPMS is a devastating progressive phase of MS, whereby patients gradually develop permanent disability. Clinical response to IFN treatment in SPMS patients is heteroge- neous and overall IFN is unable to prevent ...
8
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
... bioactive metabolite of sphingosine in vivo, which binds to a family of G-protein-coupled receptors consisting of five distinct subtypes (S1PR1–S1PR5) expressed differentially on the surface of several cell types, eg, ...
5
Drug repurposing : a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis
... lateral sclerosis”>, limited to publication metatags of “human” and “clinical trial” where these filters were ...used: multiple sclerosis, Alzheimer’s dis- ease, motor neuron disease, amyotrophic ...
18
Characterisation of tissue type metabolic content in secondary progressive multiple sclerosis : a magnetic resonance spectroscopic imaging study
... Proton magnetic resonance spectroscopy yields metabolic information and has proved to be a useful addition to structural imaging in neurological diseases. We applied short-echo time Spectroscopic Imaging in a cohort of ...
8
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis : views of patients and health professionals
... … as these things get worse, you know, you’re kind of slowly having to accommodate it, and having to accept it, because you have no damn choice. But it's not easy. So when you’re then told it’s Secondary ...
26
Robust Perfusion Deficits in Cognitively Impaired Patients with Secondary Progressive Multiple Sclerosis
... Potential limitations of the present study include the lack of complete overlap between the SPM and PLS qCBV results. The discrepancy likely reflects methodologic differences between the 2 analytic techniques. PLS is ...
6
Deciphering the role of DNA methylation in multiple sclerosis: emerging issues
... Protein-tyrosine phosphatase SHP-1 may be implicated into immune system activation and inflammatory demyelination of MS patients [36]. MS patients were found to have a higher methylation level at the promoter 2 of SHP-1 ...
9
Heterogeneity of Cortical Lesion Susceptibility Mapping in Multiple Sclerosis
... This study was performed on postmortem brain tissues from 16 patients with secondary-progressive multiple sclerosis (SPMS) (mean age at death, 44.4 ⫾ 6.2 years, Table 1; disease duration, ...
9
Magnetic resonance imaging evaluation and therapeutic trials in primary progressive multiple sclerosis
... Although multiple sclerosis has been clinically characterised for over 150 years, its aetiology and pathophysiology are still poorly ...in multiple sclerosis has therefore remained in its ...
208
An Atypical Presentation of Multiple Sclerosis
... of Multiple Sclerosis: There are four categories of disease described: relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis ...
5
Title: EMERGING TRENDS IN PHARMACEUTICALS: NANOTECHNOLOGY Author: Mr. Kashyap Nagariya Keyword: Guest EditorialPage No: i-iiDownload PDF
... the blood brain barrier [47]. Therapy with interferon beta leads to a reduction of neuron inflammation Moreover, it is also thought to increase the production of nerve growth factor and improve neuronal survival. ...
10
Parkinsonism associated with multiple sclerosis: A report of eight new cases and a review on the literature.
... In this study, we identified eight MS patients (five women and three men) presented with the symptoms of PD. Demographic and clinical details of patients are summarized in table 1. The mean (±SD) age of onset was 33.3 ± ...
6
Multiple Sclerosis: A Review of Existing Therapy and Future Prospects
... Interferon beta-lb (Betaseron): Interferon beta-lb is now being tested in a clinical trial for the treatment of secondary progressive MS. This is a huge randomized study involving thirty centers in North ...
8
Gray Matter n Acetyl Aspartate Deficits in Secondary Progressive but Not Relapsing Remitting Multiple Sclerosis
... called secondary progres- sive MS (SPMS). This progressive phase is marked by unrelenting physical and cognitive decline, implicat- ing neuronal ...primary progressive course, marked by a continuous, ...
5